QALSODY
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.9M | 372 | 263 |
| 2023 | $57,201 | 12 | 9 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.9M | 35 | 99.4% |
| Food and Beverage | $11,250 | 339 | 0.4% |
| Consulting Fee | $5,085 | 2 | 0.2% |
| Education | $559.87 | 8 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3 Randomized, Placebo-Controlled Trial of Tofersen in Adults with a Confirmed Mutation in the Superoxide Dismutase 1 Mutation Gene Who Are Clinically Presymptomatic for Amyotrophic Lateral Sclerosis with a Longitudinal Natural History Run-in and Open-Label Extension | Biogen, Inc. | $1.5M | 3 |
| An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect of Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation | Biogen, Inc. | $1.4M | 0 |
| A Phase 1 Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB067 Administered to Adult Subjects with Amyotrophic Lateral Sclerosis. | Biogen, Inc. | $1,794 | 0 |
Top Doctors Receiving Payments for QALSODY — Page 11
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Body Imaging | Fort Worth, TX | $15.43 | 1 |
| , CNP | Family | Springfield, AR | $15.34 | 1 |
| , APRN | Family Medicine | Fort Smith, AR | $15.34 | 1 |
| , M.D | Neurology | Edinburg, TX | $14.91 | 1 |
| , FNP | Nurse Practitioner | Edinburg, TX | $14.91 | 1 |
| , NP-C | Nurse Practitioner | Chesterfield, MO | $14.72 | 1 |
| , M.D | Neurology | Chesterfield, MO | $14.72 | 1 |
| , MD | Student in an Organized Health Care Education/Training Program | Searcy, AR | $14.28 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | Searcy, AR | $14.28 | 1 |
| , PA-C | Surgical | Searcy, AR | $14.28 | 1 |
| , MD | Developmental - Behavioral Pediatrics | Columbia, MO | $13.08 | 1 |
| , FNP-BC | Family | Columbia, MO | $13.08 | 1 |
| , M.D | Physical Medicine & Rehabilitation | Columbia, MO | $13.08 | 1 |
| , PA | Physician Assistant | Brooklyn, NY | $12.95 | 1 |
| , DO | Neurology | Brooklyn, NY | $12.95 | 1 |
| , RPA-C | Physician Assistant | Brooklyn, NY | $12.95 | 1 |
| , N.P | Nurse Practitioner | Bedford, TX | $10.88 | 1 |
| , M.D., MPH | Neurology | Bedford, TX | $10.88 | 1 |
| , MD | Neurology | Baton Rouge, LA | $7.42 | 1 |
| , FNP | Registered Nurse | El Paso, TX | $6.98 | 1 |
| , M.D | Neurology | Bedford, TX | $6.49 | 1 |
Manufacturing Companies
- Biogen, Inc. $2.9M
Product Information
- Type Drug
- Total Payments $2.9M
- Total Doctors 270
- Transactions 384
About QALSODY
QALSODY is a drug associated with $2.9M in payments to 270 healthcare providers, recorded across 384 transactions in the CMS Open Payments database. The primary manufacturer is Biogen, Inc..
Payment data is available from 2023 to 2024. In 2024, $2.9M was paid across 372 transactions to 263 doctors.
The most common payment nature for QALSODY is "Unspecified" ($2.9M, 99.4% of total).
QALSODY is associated with 3 research studies, including "A Phase 3 Randomized, Placebo-Controlled Trial of Tofersen in Adults with a Confirmed Mutation in the Superoxide Dismutase 1 Mutation Gene Who Are Clinically Presymptomatic for Amyotrophic Lateral Sclerosis with a Longitudinal Natural History Run-in and Open-Label Extension" ($1.5M).